<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Future - Research Project</title>
    <link rel="stylesheet" href="style.css">
    <link rel="stylesheet" href="animation.css">
</head>
<body>
    <!-- 顶部导航栏 -->
    <header class="topbar">
        <div class="topbar-inner container">
            <!-- 品牌链接 -->
            
            <div class="nav-desktop">
                <a href="index.html">Home</a>
                <a href="project.html">Project</a>
                <a href="design.html">Design</a>
                <a href="feasibility.html">Feasibility</a>
                <a href="method.html">Method</a>
                
                <a href="result.html">Result</a>
                <a href="about.html">About Us</a>
                <a href="future.html" class="active">Future</a>
                <a href="elsi.html">ELSI</a>
            </div>
            <!-- 汉堡菜单按钮 -->
            <button class="hamburger">
                <span class="ham-line"></span>
                <span class="ham-line"></span>
                <span class="ham-line"></span>
            </button>
        </div>
    </header>

    <!-- 移动端菜单 -->
    <div class="mobile-menu">
        <nav class="mobile-nav">
            <a href="index.html">Home</a>
            <a href="project.html">Project</a>
            <a href="design.html">Design</a>
            <a href="feasibility.html">Feasibility</a>
            <a href="method.html">Method</a>
           
            <a href="result.html">Result</a>
            <a href="about.html">About Us</a>
            <a href="future.html">Future</a>
            <a href="elsi.html">ELSI</a>
        </nav>
    </div>

    <!-- 主内容区域 -->
    <main class="container">
        <!-- Future部分 -->
        <section class="section no-border" id="future">
            <div class="emphasis-title text-centered">
                <h2>Future</h2>
            </div>
            
            <!-- 1. In Vivo Studies -->
            <div class="subhead">1. In Vivo Studies</div>
            
            <div class="text-col">
                <p class="para-title">Antimicrobial Efficacy:</p>
                <p>
                    Animal models, including murine pneumonia,
                    infected cutaneous wound, and vaginitis models<sup>[1]</sup>, will be utilized to
                    evaluate the antibacterial performance of antibiotic nanozymes across
                    various tissue sites.
                </p>
                
                <p class="para-title">Safety Assessment:</p>
                <p>
                    In vivo studies will be conducted to assess potential
                    hepatotoxicity, immunogenicity, and plasma stability of the antibiotic
                    nanozymes<sup>[2]</sup>.
                </p>
            </div>
            
            <!-- 2. Targeted Antifungal Activity -->
            <div class="subhead">2. Targeted Antifungal Activity</div>
            
            <div class="text-col">
                <p>
                    Given that β-glucan is a key structural component of the fungal cell
                    wall<sup>[3]</sup>, antibiotics with specific affinity for glucan can be selected
                    to enable targeted antifungal activity. These antibiotics will then be
                    integrated with hemin to construct nanozymes, allowing for systematic
                    evaluation of their antifungal efficacy in a targeted manner.
                </p>
            </div>
            
            <!-- 3. Clinical Translation -->
            <div class="subhead">3. Clinical Translation</div>
            
            <div class="text-col">
                <p>
                    Compared with conventional antibiotic monotherapy, antibiotic nanozymes
                    exhibit significantly enhanced bactericidal activity, enable dose
                    reduction, and demonstrate the ability to reverse bacterial
                    resistance<sup>[4]</sup>. Future efforts will focus on collaboration with
                    clinical institutions to advance therapeutic translation.
                </p>
            </div>
        </section>

        <!-- Is that all? 部分 -->
        <section class="section" id="additional-considerations">
            <div class="subhead text-centered">Is that all?</div>
            
            <!-- 1. Preparation Scalability -->
            <div class="subhead">1. Preparation Scalability</div>
            
            <div class="text-col">
                <p>
                    The coordination coprecipitation process offers straightforward,
                    efficient, and scalable synthesis<sup>[5]</sup>. Its essential steps, including
                    mixing, reaction, and separation, can be seamlessly scaled from
                    laboratory to industrial scale, preserving process integrity throughout.
                </p>
            </div>
            
            <!-- 2. Economic Viability -->
            <div class="subhead">2. Economic Viability</div>
            
            <div class="text-col">
                <p>
                    The production process offers a primary economic advantage, deriving
                    from the low material costs and ready availability of essential reagents
                    such as antibiotics and hemin. This cost-effectiveness is further
                    enhanced at an industrial scale, where bioreactors with precise control
                    over temperature, pH, and agitation will ensure consistent product
                    quality and high reproducibility without significant cost escalation.
                </p>
            </div>
        </section>

        <!-- Reference部分 -->
        <section class="section" id="references">
            <div class="subhead">Reference:</div>
            
            <div class="text-col references">
                <div class="refs">
                    <p>[1] Xu Z, He X, Gui Y, et al. Intrapleural pressure-controlled piezo-catalytic nanozyme for the inhibition of malignant pleural effusion[J]. Nature Communications, 2025, 16(1):1-13.</p>
                    
                    <p>[2] Zhang S, Gao XJ, Ma Y, et al. A bioinspired sulfur-Fe-heme nanozyme with selective peroxidase-like activity for enhanced tumor chemotherapy[J]. Nature Communications, 2024, 15(1):1-14.</p>
                    
                    <p>[3] Liu X, Wang Y, Zhang H, et al. Molecular architecture of chitin and chitosan-dominated cell walls in zygomycetous fungal pathogens by solid-state NMR[J]. Proceedings of the National Academy of Sciences, 2025, 122(11):e2417949122.</p>
                    
                    <p>[4] Yuan Y, Chen L, Song K, et al. Stable peptide-assembled nanozyme mimicking dual antifungal actions[J]. Nature Communications, 2024, 15(1):1-13.</p>
                    
                    <p>[5] Qin L, Gan J, Niu D, et al. Interfacial-confined coordination to single-atom nanotherapeutics[J]. Nature Communications, 2022, 13(1):1-10.</p>
                </div>
            </div>
        </section>
    </main>

    <!-- 页脚 -->
    <footer class="site-footer">
        <div class="container">
            <p>&copy; 2025 Antibiotic Nanozyme Research Project.</p>
        </div>
    </footer>

    <script src="scripts.js"></script>
</body>
</html>